April 23, 2020 -- Fujifilm Diosynth Biotechnologies has partnered with Oxgene to deliver gene therapy products with a 25% reduction in production time, the company reported on April 23.
Fujifilm Diosynth, a contract development and manufacturing organization, has licensed Oxgene's proprietary adeno-associated virus (AAV) gene therapy system. The system consists of helper, rep/cap, and gene of interest plasmids, used in combination with a clonal suspension of a HEK293 cell line.
Fujifilm Diosynth will manufacture and stock supplies for clients engaged in process development and good manufacturing practice (GMP) manufacture of gene therapy programs at its site in College Station, TX. Plans for additional in-house gene of interest plasmid manufacturing facilities are set to begin in late 2020.
The partnership will reduce the length of the supply chain for Fujifilm Diosynth clients, which is often a bottleneck for process development of novel gene therapies. With the arrangement, lead-time from the start of process development to the first GMP manufacture can be reduced by three to six months.